Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain, on June 12-15, 2019. Among the abstracts to be presented are 24 week interim results from the ongoing FINCH 1 and FINCH 3 Phase 3 studies evaluating filgotinib in adults with rheumatoid arthritis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190529005911/en/
“These data reinforce our belief that filgotinib has the potential to make a meaningful difference for patients with rheumatoid arthritis, both early and also late in the course of treatment when other treatments have failed,” said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research and Development, Gilead Sciences. “The FINCH results reflect the growing strength and breadth of Gilead’s inflammation pipeline and our commitment to improving the outlook for patients living with inflammatory diseases – both with filgotinib and our other investigational compounds.”
“This meeting marks our first opportunity to present the results from the FINCH 1 and 3 filgotinib trials in rheumatoid arthritis,” said Dr. Walid Abi-Saab, Chief Medical Officer, Galapagos. “These results show the potential of filgotinib in helping to address the unmet need for people living with this debilitating disease.”
Phase 3 Trials of Filgotinib in Rheumatoid Arthritis
Detailed 24 week interim results from the Phase 3 FINCH 1 and 3 clinical trials will both be presented for the first time in oral sessions at the conference. Top-line data from these studies were announced earlier this year. Findings from FINCH 1 will be presented in the opening plenary session, while FINCH 3 results will be presented in the late-breaking abstract session.
- Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results (oral #LB0001 4:25pm CET, 12 June, Hall 6)
- Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results (oral #LB0003 8:00am CET, 15 June, Hall 7B)
FINCH 1 is an ongoing, randomized, double-blind, placebo- and active-controlled Phase 3 study evaluating filgotinib versus adalimumab or placebo in adults with moderately-to-severely active rheumatoid arthritis on a stable background dose of methotrexate but with a prior inadequate response to methotrexate. The study achieved its primary endpoint at both 100 mg and 200 mg doses of filgotinib, in the proportion of patients achieving an American College of Rheumatology (ACR) 20 percent response (ACR20) compared with placebo at Week 12.
The proportion of patients achieving an ACR 50 percent response (ACR50) or ACR 70 percent response (ACR70) was significantly greater for filgotinib compared with placebo at Week 12, for both doses. The study also achieved key secondary endpoints, including significant inhibition of radiographic progression with both doses of filgotinib versus placebo.
FINCH 3 is an ongoing, randomized, double-blind, active-controlled Phase 3 study of filgotinib in adults with moderately-to-severely active rheumatoid arthritis. The trial evaluated filgotinib in combination with methotrexate and as monotherapy in methotrexate-naïve patients. The study achieved its primary endpoint, with a significantly higher proportion of patients reaching ACR20 in the filgotinib plus methotrexate groups compared with patients receiving methotrexate alone. Additionally, both doses of filgotinib demonstrated significantly higher ACR 50 and ACR 70 responses than methotrexate alone.
In both trials, filgotinib demonstrated a safety profile consistent with previously reported results.
Additional abstracts accepted for presentation at the meeting include:
- Filgotinib in Patients with Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biologic DMARDs (bDMARD-IR) by Geographic Region and Race (poster #THU0173)
- Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib Modulates the Disease-associated Whole Blood Transcriptional Profile of Patients with Active Rheumatoid Arthritis (poster #THU0194)
- Safety and Efficacy of Filgotinib in Active Rheumatoid Arthritis by Prior Biologic DMARD Exposure in Patients with Prior Inadequate Response or Intolerance to Biologic DMARDs (bDMARD-IR) (poster #FRI0092)
- Filgotinib, a Selective Janus Kinase 1 (JAK1) Inhibitor, Modulates Disease-associated Cytokines in Patients with Active Rheumatoid Arthritis (poster #FRI0113)
- Safety and Efficacy of Filgotinib in Patients Aged 65 Years and Older: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biologic DMARDs (bDMARD-IR) (poster #FRI0154)
Additional Data on Filgotinib in Inflammatory Disease Management
In addition to the FINCH studies, Gilead and Galapagos will present results from EQUATOR, a Phase 2, placebo-controlled, double-blind study of filgotinib among patients with active psoriatic arthritis; additional clinical data on filgotinib in individuals with hepatic impairment; and preclinical data characterizing filgotinib among JAK inhibitors and in combination with an ASK1 inhibitor.
- Efficacy of Filgotinib vs. Placebo in Active Psoriatic Arthritis: Patient-Level Data from EQUATOR, a Randomized, Phase 2 Study (oral #OP0109)
- Filgotinib Treatment Provides Rapid and Sustained Reduction of Inflammatory Biomarkers in Moderate to Severe Psoriatic Arthritis (PsA) Patients (poster #THU0031)
- PsAID9 in Patients with Active Psoriatic Arthritis Treated with Filgotinib vs Placebo: Results from EQUATOR, a Randomized, Phase 2 Study (poster #SAT0367)
- Effect of filgotinib on Patient-reported Outcomes in Active Psoriatic Arthritis: Results from EQUATOR, a Randomized, Phase 2 Study (poster #SAT0373)
- In Vitro Mechanistic Studies Demonstrate Filgotinib Activity that Has Potential Implications for Differentiation among JAK Inhibitors (poster #THU0017)
- Pharmacokinetics and Short-Term Safety of Filgotinib, a Selective Janus Kinase 1 Inhibitor, in Subjects with Moderate Hepatic Impairment: a Phase 1, Open-label, Single-arm Study (poster #THU0117)
- Targeting Activated ASK1 in Synovial Fibroblasts in Combination with Jak1 Inhibition Enhances Efficacy in Rat CIA (poster #THU0014)
Filgotinib is an investigational agent and is not approved by the U.S. Food and Drug Administration or any other regulatory authority. Its efficacy and safety have not been established.
About the Galapagos – Gilead Collaboration
Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. The FINCH studies are among several clinical trials of filgotinib in inflammatory diseases, including the EQUATOR Phase 2 program in psoriatic arthritis, the TORTUGA study in ankylosing spondylitis, the DIVERSITY Phase 3 trial in Crohn’s disease (also small bowel and fistulizing Crohn’s disease Phase 2 studies) and the Phase 3 SELECTION trial in ulcerative colitis.
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
Galapagos Forward-Looking Statements
This release may contain forward-looking statements with respect to Galapagos, including statements regarding Galapagos’ strategic ambitions, the mechanism of action and potential safety and efficacy of filgotinib, the anticipated timing of clinical studies with filgotinib and the progression and results of such studies. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos’ results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of filgotinib due to safety, efficacy or other reasons), Galapagos’ reliance on collaborations with third parties (including its collaboration partner for filgotinib, Gilead), and estimating the commercial potential of Galapagos’ product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos’ Securities and Exchange Commission (SEC) filings and reports, including in Galapagos’ most recent annual report on Form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
Gilead Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from ongoing and additional clinical trials involving filgotinib. Further, it is possible that the parties may make a strategic decision to discontinue development of filgotinib, and as a result, filgotinib may never be successfully commercialized. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Sofie Van Gijsel
+32 485 19 14 15
Senior Director Communications
+32 473 824 874
+31 6 53 591 999
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Velodyne Files Patent Infringement Complaint with ITC Against Hesai and RoboSense16.8.2019 12:00:00 CEST | Press release
Velodyne Lidar, Inc. filed a patent infringement complaint with the U.S. International Trade Commission (ITC) against Hesai Photonics Technology Co., Ltd. and Suteng Innovation Technology Co., Ltd. (a.k.a. RoboSense) for violations of section 337 of the Tariff Act of 1930 which makes unfair methods of competition and importation of certain products into the United States unlawful. Earlier this week, Velodyne also filed patent infringement complaints against Hesai and RoboSense in the U.S. District Court for the Northern District of California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005041/en/ Velodyne Lidar’s Alpha Puck™, Ultra Puck™ and Puck™ surround view sensors (left to right). (Photo: Business Wire) Velodyne is asking the ITC to investigate these lidar manufacturers for unlawfully importing and selling lidar sensors that infringe Velodyne’s patented lidar technology (U.S. Patent 7,969,558). Velodyne reques
Merz Announces Key Governance Changes16.8.2019 09:26:00 CEST | Press release
Merz, a global leader in medical aesthetics and specialty neurology, announced today that Philip Burchard will be appointed Chairman of the company’s Shareholders Council. He will assume this role in addition to his current position as Chief Executive Officer of the Merz Healthcare Group. In his new position, Philip Burchard will succeed Andreas Krebs, who has decided to step down from his current roles as Chairman of the Shareholders Council and Supervisory Board of Merz in order to dedicate more time to his personal entrepreneurial and philanthropic activities. In addition, Dr. Christian Holzherr will be the new Chairman of the Merz Supervisory Board. All changes will be effective as of October 31, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005106/en/ Philip Burchard, CEO of Merz (Photo: Business Wire) Philip Burchard joined Merz as CEO in July 2012. Under his leadership, Merz has focused its strategy on ae
FINEOS lists on the Australian Securities Exchange16.8.2019 07:22:00 CEST | Press release
FINEOS Corporation Holdings plc (ASX:FCL), a leading provider of group and individual core systems for life, accident and health insurance, today announced the commencement of trading on the Australian Securities Exchange (ASX) via an initial public offering (IPO). The total number of securities (CHESS Depository Interests or “CDIs”) on offer was 84.4 million at a price of A$2.50 per CDI. Total gross proceeds from the offer amounted to A$211 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005058/en/ FINEOS lists on the Australian Securities Exchange (Photo: Business Wire) FINEOS intends to use the net proceeds from the IPO to invest further in R&D to grow the FINEOS product footprint and develop new business lines, to invest in additional sales, marketing and client account management capabilities and to pay down existing debt and shareholders selling down. Key areas of growth strategy for FINEOS include: • Inc
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis15.8.2019 20:01:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005605/en/ “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievem
Celsius Network Partners With Bitcoin.com15.8.2019 14:55:00 CEST | Press release
Celsius Network, the industry-leading cryptocurrency platform, has announced a new partnership with Bitcoin.com, the leading resource for Bitcoin trading, news, and updates. Users of Celsius services are now able to purchase BCH, BTC, ETH, and other mutually supported cryptocurrencies through the Celsius app using Bitcoin.com’s advanced crypto trading platform providing low fees, enhanced accessibility to cryptocurrency, and valuable crypto services. With the shared mission of making financial services fair, rewarding, and transparent, Celsius and Bitcoin.com are well-known in the space for offering inclusive services designed to support the needs and interests of their robust communities. Celsius members can earn interest income of up to 10.53% APR on crypto assets and use their coins as collateral to get dollar loans at rates as low as 4.95% without fees or penalties, no minimums or caps, and no lockups. Bitcoin.com makes it easy to buy dozens of crypto assets instantly and without f
Anesthesia Patient Safety Foundation and Patient Safety Movement Foundation Offer $100,000 Patient Safety Curriculum Award15.8.2019 12:58:00 CEST | Press release
The Anesthesia Patient Safety Foundation (APSF), in partnership with the Patient Safety Movement Foundation (PSMF), is now accepting proposals for the Patient Safety Curriculum Award. The $100,000 award will go to an anesthesia education investigator with the intent to modify the PSMF Patient Safety Curriculum to address perioperative patient safety. The awardee will also test the educational efficiency and effectiveness of implementing the curriculum in anesthesia training programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005377/en/ Anesthesia Patient Safety Foundation and Patient Safety Movement Foundation Offer $100,000 Patient Safety Curriculum Award (Graphic: Business Wire) “This important work will add to the considerable value provided by PSMF’s Patient Safety Curriculum,” said Mark Warner, APSF President. “To ensure the safety of patients and achieve our collective goal of zero preventable deaths in hosp